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ABSTRACT Bone morphogenetic proteins (BMPs) are involved with a wide range of processes including apoptosis, differen-
tiation, and proliferation. Several different pathways such as Smad, p38, and PI3/Akt are activated by BMPs. Signaling is trans-
duced by BMP receptors (BMPRs) of type I and type II that are serine/threonine kinase receptors. BMPRs shuttle between
membrane domains such as caveolae enriched with caveolin-1 b-isoform and caveolae of the caveolin-1 a/b-isoforms. It is
hypothesized that there are other membrane domains to which the receptors localize. We used immunoprecipitation, Western
blots, image cross-correlation spectroscopy, and ﬂuorescence resonance energy transfer to investigate the interaction of BMPRs
with proteins in clathrin-coated pits (CCPs). Our data indicate that these domains are associated with at least two of the BMPRs:
BRIa and BRII. For the ﬁrst time, to our knowledge, we showed what we believe are speciﬁc interactions between BRIa and BRII
with a key component of CCPs, adaptor protein 2. Further, disruption of CCPs resulted in increased BRIa aggregation at the cell
surface and activation of the BMP pathway even in the absence of BMP2. Therefore, CCPs seem to function as a negative regu-
latory membrane domain for BMP pathway activation.INTRODUCTION
The bone morphogenetic proteins (BMPs) form a subgroup
of the transforming growth factor-b superfamily of ligands.
They are crucial not only during skeletal development but
also during neurogenesis, hematopoiesis, and bone remodel-
ing. At the cellular level, BMPs regulate a variety of pro-
cesses such as apoptosis, differentiation, and proliferation
(1–3). BMPs are a large family of cytokines that transduce
their signal via serine/threonine kinase transmembrane
receptors (4–6). Activation of the signaling pathway is initi-
ated by the binding of ligands to the type-I and type-II recep-
tors followed by phosphorylation of the type-I receptor by
the type II receptor, a constitutive active kinase (7). The
most examined pathway is Smad, in which the signal is
mediated to the nucleus via a heterodimer complex of
Smad1, Smad5, and Smad8 (regulatory Smads (R-Smads))
with Smad4 (1–3,8,9). Other pathways include the p38,
and ID1 PI3 (phosphatidylinositol 3-kinase)/AKT, ERK
(extracellular signal-related kinases), JNK (c-Jun N-terminal
kinase), NF-kb (Nuclear Factor kb), pathways (4,9–13).
There are numerous distinct mechanisms that provide
negative feedback loops of the BMP pathways. Several
BMP antagonists, such as noggin and follistatin, have been
identified in the extracellular compartment (9,14). At the
cell surface BAMBI (BMP and activin bound protein),
a transmembrane glycoprotein, associates with BMPRs and
inhibits activation of type-I receptors. Inside the cell,
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0006-3495/09/09/1428/8 $2.00Smad6 and Smad7, which are inhibitory Smads, regulate
the Smad pathway by BMP dependent upregulation and
blocking of R-Smad phosphorylation (9). In addition, BMP
signaling is regulated at the cell surface by caveolae, which
are flask-shaped invaginations of the plasma membrane.
BMPRs localize to these domains and shuttle between
caveolin isoforms, CAV-1ab and CAV-1b. Binding of
BRII to the caveolin-1 scaffolding domain, phosphorylation
of caveolin-1, or downregulation of caveolae all inhibit BMP
signaling (9,15,16).
Previous results showed that 25% of BRII and 40% of
BRIa colocalize with caveolae (16) raising the question
whether there are other, still unidentified, target signaling
areas that regulate BMPR recycling, storage, and key
signaling events. Clathrin-coated pits (CCPs) are involved
with receptor recycling and BMP signaling. The use of
nonspecific chemical and mechanical treatments of the
plasma membrane to disrupt CCPs showed stimulation of
BMP signaling (17) whereas Hartung et al. (4) and Billings
et al. (18) showed an inhibition of BMP signaling. However,
more specific treatments for CCPs disruption must be
applied to delineate the exact role of CCPs in BMP signaling.
Receptor recycling via CCPs is carried out in three main
steps by the cell. First is formation of nucleation sites. These
sites form from adaptor proteins such as adaptor protein
complex 2 (AP2) binding to phosphatidylinositol 4,5
bisphosphate (PtdIns-4,5-P2) and internalizing domains of
cargo proteins (19–22). Other adaptor proteins include auto-
somal recessive hypercholesterolemia discontinuous actin
hexagon, b-arrestin, numb, epsin, Eps15 (epidermal growth
factor receptor pathway substrate clone 15), clathrin
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tin-interacting protein 1 related protein). Second is recruit-
ment of clathrin by adaptor proteins. Third is the vesicle
pinching off from the membrane surface by the GTPase, dy-
namin, and then coat dissociation (19–21,23).
Eps15 was identified previously as a BRII interacting
protein suggesting a role for Eps15 in CCP mediated
BMPR recycling during the early steps of endocytosis.
However, key proteins that regulate later events such as
recruitment of clathrin and pit formation for BMPRs have
yet to be identified. In this study, we provide evidence for
what we believe is a new protein receptor interaction
between BMPRs and AP2. We show with the family of
image correlation spectroscopy and fluorescence resonance
energy transfer (FRET) that BRIa and BRII bound AP2 inde-
pendently of each other. BRIa, but not BRII, increased its co-
localization with AP2 after the addition of BMP2 indicating
that AP2 recruited BRIa to CCPs. Specific disruption of
CCPs induced an activation of the Smad pathway and
increased alkaline phosphatase (ALP) expression. A known
marker for osteogenesis, ALP data suggested the disruption
of CCPs led to the initiation of osteogenesis of C2C12 cells.
These data together with our previous observations suggest
that the receptor complexes must shuttle on the membrane
surface to signal properly and CCPs is an inhibitory
membrane domain.
EXPERIMENTAL PROCEDURES
Materials
Recombinant BMP2 was obtained from R&D Systems (Minneapolis, MN).
The polyclonal goat anti-sera against the BMP receptors BRIa and BRII, the
Alexa 546 red X conjugated donkey anti-goat antibody and Alexa 488 goat
anti mouse antibody were from Santa Cruz Biotechnology (Santa Cruz, CA).
Mouse antisera against adaptin b is from Transduction Laboratories (Lex-
ington, KY). The cell lines A431 (CRL 1555) and C2C12 (CRL 1772)
were purchased from American Type Culture Collection (Manassas, VA).
Both cell types were grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 1% penicillin/streptomycin and with or
without 10% FBS as indicated in the protocols.
Transfection of A431
A431 cells grown on 35-mm dishes were transfected by the DEAE-(Diethyl-
Aminoethyl) dextran method (16). Five micrograms of DNA/plasmid were
used.
Immunoﬂuorescence labeling of cell surface
receptors
To measure the distribution of the BMP receptors on the cell surface, we
used confocal fluorescence imaging measurements. Cells were grown on
22-mm glass coverslips. A431 cells grew in DMEM without FBS. After
72 h cells were stimulated or mock-stimulated with BMP2 (40 nM) for
2.5 h. C2C12 cells were either treated with DMEM absent of potassium
or DMEM without FBS. Treated C2C12 cells were incubated overnight.
Cells were fixed by the acetone/methanol method (24). Cells were incubated
for 30 min with 5% BSA to minimize nonspecific binding. A431 and C2C12cells were incubated with polyclonal goat anti-sera recognizing either BRII
or BRIa according to manufacturer’s protocol followed by the corresponding
secondary donkey anti-goat (20 mg/mL). After each antibody labeling, cells
were washed three times with phosphate-buffered saline (PBS). They were
then incubated with mouse anti-sera against the b-subunit of AP2 (manufac-
turer’s protocol). They were incubated again with goat anti mouse antibody
at a concentration of 20 mg/mL, washed and coverslips were mounted in
Airvol (16).
Image correlation spectroscopy and image
cross-correlation spectroscopy
Image correlation spectroscopy (ICS) is the technique used to study the
distribution and localization of the BMPRs. High resolution and high magni-
fication images were collected by confocal microscopy using a 63 objec-
tive. The microscope used was a BioRad MRC 600 confocal equipped with
an argon-krypton mixed-gas laser and appropriate filter sets for dual-fluoro-
phore imaging. ICS involves autocorrelation analysis of the intensity fluctu-
ations within these confocal images, in this case from immunofluorescent
labeled proteins (25–27). From this, the cluster density (CD) was calculated
from Eq. 1 (25)
CD ¼ 1
gð0; 0Þpw2 ¼
Np
pw2
: (1)
Image cross-correlation spectroscopy (ICCS) is the tool used to quantify the
extent of colocalization between two proteins. It is based on the autocorre-
lation and cluster density from ICS. The autocorrelation is calculated for
each image separately and then the cross-correlation function is calculated
from the two images. This represents the average density of clusters in which
both proteins localize together. The fraction of one protein colocalizing with
the other can be calculated (25,27).
Immunoprecipitation and Western blots
A431 cells were serum starved to upregulate BRII (16,28). Cells were
washed twice with cold PBS and lysed at 4C for 60 min with lysis buffer
(containing 10 mM Tris pH 7.5, 50 mM NaCl, 1% Triton X-100, 60 mM
octyl glucoside, 1 mM PMSF, 10 mg/mL each of leupeptin, aprotinin,
soybean trypsin inhibitor, benzamidine-HCl, pepstatin, and antipain). Immu-
noprecipitation (IP) used 10 ng/mL of antibody for BRIa and BRII from
Santa Cruz Biotechnology and standard Western blots using the AP2 anti-
body against the b-subunit (16). As a negative control for IPs, blocking
peptides (Santa Cruz Biotechnology) were used at a 20 times higher molar
concentration to block the interaction between BRIa, BRII, and their corre-
sponding antibody.
FRET
FRET is used to study molecular scale interactions between AP2 and
BMPRs. The technique measures the energy transfer between a donor chro-
mophore (green label in Fig. 2 B) on one protein and an acceptor chromo-
phore (red label in Fig. 2 B) on the other protein. Transfer of energy can only
occur if the two chromophores (and hence the two proteins) are closer than
~100 A˚ (29,30). High resolution and high magnification images were
collected by confocal microscopy of the donor chromophore fluorescence.
The acceptor chromophore was then bleached completely and the donor
chromophore fluorescence was imaged again. The increase in intensity of
the donor fluorescence is a measure of the donor fluorescence that was
quenched by the acceptor in the energy transfer process. The energy transfer
efficiency (E) was calculated from Eq. 2 (31):
E ¼ 1  Fda=Fd; (2)
where Fda is the fluorescent intensity of the donor with the acceptor and Fd is
the fluorescent intensity of the donor after the acceptor is photobleached.Biophysical Journal 97(5) 1428–1435
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phores (R) can then be estimated by Eq. 3:
R ¼ R0ðð1=EÞ  1Þ1=6: (3)
Here, R0 is the Foerster distance, that is the distance at which energy transfer
efficiency is 50% of the maximum possible. R0 is calculated by Eq. 4 for
a particular donor-acceptor pair:
R0 ¼

8:8  1023 K2n4QdJ
1=6
: (4)
The Foerster distance depends on K, the dipole orientation factor and it is
usually assumed that K2 has a value of 2/3 corresponding to isotropic orien-
tations of the chromophores with respect to each other. The refractive index
of the medium is that of water (n ¼1.33), Qd is the fluorescence quantum
yield of the donor in water (0.85) and J is the spectral overlap integral
between donor emission and acceptor excitation spectra (J ¼ 6.68 
1013 M1 cm1 nm4 for the chromophores used here). Hence the value of
R0 was calculated to be 32 A˚ for the chromophores used in this study (32).
Luciferase reporter assay
C2C12 cells grown in 60-mm dishes were transfected with 2 mg pSBE to
measure the activity of the Smad pathway and 2 mg pRL-luc plasmids for
normalization, whereas treated cells were transfected with 1 mg of plasmid
encoding either EH29 or K44A to disrupt CCPs. Total amount of plasmid
used was limited due to volumes used with transfection method. Cells
were transfected with Lipofectamine 2000 from Invitrogen (Carlsbad, CA)
according to the manufacturer’s instructions; 4 h after transfection, cells
where indicated were treated with potassium-free media and all cells were
either stimulated with 40 nM BMP2 or mock stimulated. After 12 h of incu-
bation, cells were washed with PBS, lysed and the luciferase activity was
measured using a dual luciferase assay system (Promega, Madison, WI).
Alkaline phosphatase assay
C2C12 cells were transfected as indicated above with plasmids to disrupt
CCPs. Control cells were either stimulated with 40 nM BMP2 or mock stim-
ulated. The next day cells were lysed and scraped with 500 mL of a lysis
buffer containing 0.1% Triton X-100 and 10 mM Tris pH 7.5. Samples
were subjected three freeze/thaw cycles. Protein content was normalized
before assays were carried out; 80 mL of sample and 180 mL of assay mixture
(10% alkaline buffer solution, 4 mM MgCl2, and 18.5 mg/10 mL of p-nitro-
phenylphosphate (substrate)) were incubated together for 30 min at 37C.
Absorbances were measured at 405 nm.
Statistics
Standard error of the mean values was calculated from the raw data at the
95% confidence level. For both ICCS and FRET measurement, 40 images
were taken per slide and experiments were carried out three times to ascer-
tain reproducibility.
RESULTS
BRIa and BRII colocalized with CCPs
CCPs are involved with regulating the Smad pathway via
BMPRs, yet the mechanism is unknown. Colocalization
studies of BMPRs (BRIa and BRII) to a marker for CCPs
(AP2) were investigated in A431 cells. These cells are an
established model for BMP signaling for primary mesen-
chymal cells isolated from primary limb mesenchymal cells
at E11.25 or E11.75 (33). Labeling for AP2 will show twoBiophysical Journal 97(5) 1428–1435populations of the protein. One will be large clustering of
proteins representing CCPs and the second is a smaller clus-
tering of proteins displaying areas of nucleation sites, not yet
formed CCPs as determined by ICS by Brown et al. (24).
Whole cell (Fig. 1 A) and high magnification (Fig. 1 B)
images of labeled BRIa, BRII, and AP2 at flat plasma
membrane regions were taken with confocal microscopy.
As expected both CCPs and AP2 nucleation sites were
seen in the images (Fig. 1 B).We then used ICCS to calculate
the extent of colocalization between AP2 and either BRIa or
BRII (Fig. 1, C and D). Calculating the ratio of the density of
clusters that contain both proteins as obtained from the cross-
correlation function to the cluster density for one protein
obtained from the autocorrelation function yields the fraction
of clusters of one protein that also contain the other protein.
Both BMPRs colocalized with AP2 in the absence of BMP;
~45% of the AP2 clusters contained BRIa and 75% of the
AP2 clusters contained BRII (Fig. 1 C). On BMP2 stimula-
tion the extent of BRIa colocalization with AP2 increased
from 45% to 70% whereas there was no significant effect
of BMP2 stimulation on the colocalization of BRII with
AP2. Correspondingly, 31% of BRIa clusters contained
AP2 and 44% of BRII clusters contained AP2 in the absence
of BMP. The stimulation by BMP2 led to an increase to 52%
of AP2 colocalizing to BRIa clusters although there was no
significant change in the amount of AP2 that colocalized to
BRII clusters (Fig. 1 D). The observation is that the extent
of colocalization of BRII and AP2 is constitutively greater
than that of BRIa and AP2, but that the interaction of BRIa
and AP2 was enhanced by exposure to BMP2 whereas the
interaction of BRII and AP2 is unaffected.
BRIa and BRII both bound to AP2 in situ
The ICCS data suggested that BMPRs and AP2 colocalized
in the same domains, but cannot provide evidence that they
physically interacted at the molecular scale. However, lysates
of A431 cells immunoprecipitated with antibodies against
BRIa or BRII followed by blotting for adaptin b-subunit of
AP2 in Western blots showed that they do in fact bind to
each other (Fig. 2 A). Blocking peptides were used as
a control to show the bands were not due to nonspecific
binding. This binding of AP2 to BRIa and BRII is novel.
Therefore, we used FRET measurements to further verify
that these interactions between AP2 and BMPRs occurred
at the cell surface in living cells (Fig. 2 B). Because FRET
measures the proximity of two proteins labeled with different
chromophores within a range comparable to the dimensions
of biological macromolecules (10–100 A˚) it can be used to
differentiate between proteins that simply colocalize within
a domain and those that bind to each other within the domain.
The observed energy transfer efficiency was low, but signif-
icant at 8.5% for BRIa and AP2 and 10% for BRII and AP2
providing some evidence for direct binding. Significantly, on
stimulation with BMP2, the energy transfer efficiency
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ing of A431 cells for BRIa and AP-2.
A431 cells were labeled with an anti-
body against AP2 (b-subunit, green,
Transduction Laboratories) and BRIa
(Santa Cruz Biotechnology) followed
by a conjugated anti-mouse Alexa 488
and Alexa 546 red X conjugated donkey
anti-goat antibody (Santa Cruz Biotech-
nology). (A) Whole cell images,
a onefold magnification of A431 cells
labeled for AP2 (green), BRIa (red), or
BRII (red). (B) High magnified (five
times magnification at white box)
images of flat regions of the cell
membrane. AP2 exists in two popula-
tions; the large clusters in the images
represent CCPs (white arrows), whereas
the small clusters represent nucleation
sites of AP2 (black arrows). BRIa is
also found in two populations, colocaliz-
ing with AP2 (white arrows) or nonco-
localizing with AP2 (black arrows).
(C) Without BMP2 stimulation 45% of
BRIa clusters colocalize with AP-2 clus-
ters. BMP2 stimulation cause an aggre-
gation of BRIa and an increase in the
image also shows that AP2 as well as
BRIa is present in two populations: one
colocalizing with AP-2 and the other
independent of AP2 colocalization;
~75% of BRIa colocalizes AP-2 (p <
0.05). (D) AP2 colocalize with BRIa at
31% without BMP2 stimulation. With
BMP2 stimulation it increases to 52%.
The colocalization of AP2 to BRII is
unchanged with stimulation, from 44%
to 40% (p < 0.05).doubled to 17% (p < 0.05) for BRIa and AP2 but remained
unaffected for BRII and AP2. This increase in energy transfer
could arise from either of two effects—a decrease in the
average separation of the chromophores (decrease in R) or
an increase in the number of pairs of molecules that interact.
The latter is consistent with the observation from ICCS that
there was an increase in the number of BRIa and AP2
proteins that interacted in the domains and no change in
the number of BRII and AP2 proteins that interacted.
Disruption of CCPs activated the Smad pathway
Because AP2 was functionally involved with the formation
of CCPs and bound to the BMPRs, this binding interaction
may have a role for BMPR function. Consequently, we
used reporter gene assays to measure the effect on activationof Smad in C2C12 cells caused by different modes used to
disrupt CCPs. Similar to mesenchymal stem cells, C2C12
cells are pluripotent and can be differentiated into osteo-
blasts, adipocytes, and myoblasts (34,35). The addition of
BMP2 causes the C2C12 cells to differentiate into osteo-
blasts (36,37). Cells were transfected with pSBE (a plasmid
for Smad binding element) and pRL-luc (a plasmid used to
normalize the luminescence). Disruption of CCPs was
carried out by depletion of potassium and by transfection
with mutant plasmids of Eps15 (EH29) or dynamin
(K44A). The depletion of intracellular potassium disrupts
the coated pits on the surface (38,39). EH29 disrupts the
assembly of CCPs and K44A inhibits the endocytosis of
CCPs (4,10,19,20,40). All three treatments led to significant
(p < 0.05) activation of the BMP pathway as measured by
the pSBE activation assay in the absence of BMP2 (Fig. 3 A).Biophysical Journal 97(5) 1428–1435
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EH29 resulted in 2.5-fold increase and K44A led to a four-
fold increase of activation of the Smad pathway. Addition
of BMP2 led to further activation in most cases, but the effect
of BMP2 was less in those cases where the coated pit disrup-
tion led to large levels of activation and BMP2 caused no
additional activation in the K44A transfected system. The
integrity of the CCPs seems to be an important mechanism
for controlling the level of activation of this Smad pathway,
and it is possible that the AP2 interactions with BRIa and
FIGURE 2 BRIa and BRII interact with AP2 at cell surface. (A) A431
cells were treated as described previously to upregulate BRII. Cells were
lysed using a lysis buffer containing 1% Triton and BRIa or BRII immuno-
precipitated using 10 ng/mL antibody for BRIa or BRII (lanes 1 and 2; Santa
Cruz Biotechnology) followed by Western blot using an antibody against the
b-subunit of AP2 according to manufacturers protocol. AP2 was detected at
106 kDa. Lane 3 shows the positive control (Immunoprecipitation and detec-
tion with the AP2 antibody). As controls blocking peptides (BP) for the IP
antibody binding sites of BRIa or BRII were added to the lysis buffer at
a 20x higher molar concentration (lanes 4 and 5). Bands were detected using
ECL (Pierce, Rockford, IL). (B) BMP2 stimulated or unstimulated A431
cells were dual labeled with polyclonal goat anti BRIa and mouse anti adap-
tin b followed by a conjugated anti mouse Alexa 488 and donkey anti goat
Alexa 546 red antibodies. Three 40 high magnification images of flat
regions of the cell membrane labeled for the b-subunit of AP2 and BRIa
or BRII were collected. After bleaching of the acceptor chromophore
(red), images were again collected and the increase in intensity in the donor
(green) was calculated. From this, we calculated the energy transfer effi-
ciency (ET), which is the difference in the intensity between the intensity
of the donor before and after bleaching normalized to the intensity of the
bleached donor image (p < 0.05).Biophysical Journal 97(5) 1428–1435BRII inhibit their constitutive levels of activation of Smad
pathways.
CCP disruption initiated osteoblast differentiation
Although the Smad pathway is activated with the disruption
of CCPs, it is not clear if it could drive osteoblast differenti-
ation. An early marker for osteoblast differentiation is ALP
(37,41). Cells were transfected with either EH29 or K44A
and the ALP assay was carried out with normalized samples.
Alkaline phosphatase activity was increased significantly
with the addition of BMP2 compared to control cells without
BMP2, a fourfold increase (Fig. 3 B). The transfected cells
with either EH29 or K44A to disrupt CCPs also expressed
significantly higher ALP. EH29 showed a significantly
FIGURE 3 Disruption of CCPs induces BMP2-independent signaling and
an early osteoblast marker. (A) C2C12 cells were transfected with the pSBE
plasmid that is a reporter sensitive to the Smad signaling pathway, EH29,
a mutation of Eps15 protein to prevent CCP formation, or K44A, a dominate
negative dynamin to prevent endocytosis (4,10,19,20,40); 4 h after transfec-
tion cells were stimulated with or without BMP2 in DMEM, or potassium-
free medium. As can be seen the disruption of the CCPs lead to the induction
of signaling, even without BMP2 (p < 0.05). Addition of BMP2 after
disruption of the CCPs led to a slight increase in signaling and no additional
signal was seen with the K44A transfected system. (B) C2C12 cells were
transfected either with the mutation of Eps15, EH29, or K44A, dominate
negative dynamin, to prevent CCP formation and endocytosis. After 4 h,
control cells were either mock or stimulated with BMP2. The ALP activity
was increased for BMP2 stimulated cells as well as the cells transfected with
plasmids encoding EH29 and K44A (p < 0.05). The data in this graph were
verified by three independent experiments.
Novel Interaction: BMP Receptors and AP2 1433higher ALP, and K44A showed a higher ALP, threefold and
twofold, respectively (Fig. 3 B). The disruption of CCPs with
EH29 initiated osteoblast differentiation.
Aggregation of BRIa with disruption of CCPs
The CCPs serve in part to recycle receptors from the cell
surface. Disruption of CCPs could lead to an accumulation
of expressed BRIa (or BRII) at the cell surface causing the
higher level of activity. To address this, high resolution
confocal images of the membrane surface were taken of
C2C12 cells labeled for BRIa after treatment with potas-
sium-free medium. Then ICS analysis was carried out to
calculate the relative number of BRIa molecules at the
membrane and their distribution. The relative expression
levels, as measured by total fluorescence intensities, were
unaffected by potassium depletion (Fig. 4 A). However, the
distribution was altered significantly (Fig. 4 B) because
the potassium depletion caused a threefold decrease in the
cluster density. These observations showed that it is not
the total number of BRIa proteins, but their distribution on
the surface that is affected by the disruption of the CCPs.
We concluded, therefore, that the BMP2-independent activa-
FIGURE 4 Surface BRIa aggregation altered due to disruption of CCPs.
Unstimulated C2C12 cells were fixed and antibodies, polyclonal goat anti
BRIa followed by Alexa 546, were used to label BRIa. Three 40 images
were collected after treatment as indicated. The images were subjected to
ICS analysis. (A) No significant reduction or increase in the protein expres-
sion at the cell surface of BRIa compared to control was observed. (B)
Normalized results to the control value indicated BRIa cluster density
decreased with the treatment of potassium-free media.tion of Smad caused by disruption of the CCP was caused by
a further aggregation of BRIa into a smaller number of larger
clusters. It is possible that the AP2-BRIa interaction in the
CCP serves to prevent BRIa-BRIa interactions that could
lead to constitutively active receptors with no sensitivity to
BMPs.
DISCUSSION
The mechanisms responsible for BMP activation at the
membrane-receptor level are poorly understood. It seems
that BMPRs must move and rearrange on the membrane
surface to transduce their signal. Previous studies showed
that BRIa and BRII are partly localized in caveolae (16).
The CAV-1 b-isoform was shown to inhibit BMP signaling,
whereas the CAV-1 a-isoform did not affect signaling in
A431 cells. Although 25% of BRII and 40% of BRIa shuttle
between these different isoforms to transduce a signal (16),
there remains a high percentage of clustered BMPRs that
are not present in caveolae domains. This raises the question
of the involvement of other distinct domains such as CCPs in
the activation, inactivation or silencing of the receptors.
Both BRIa and BRII colocalize with AP2 without BMP
stimulation to the extent of 45% and 75%, respectively.
These results indicate that these receptors are found within
CCPs regardless of activation status. However, on BMP2
stimulation there is an increase of BRIa colocalization with
AP2 to 70% suggesting a role for CCPs in BMP signaling.
BMP2 stimulation had no effect on the colocalization of
BRII with AP2.
Direct interactions of AP2 with BRIa and BRII were shown
with immunoprecipitation studies followed by Western blots.
FRET data confirmed that these interactions occur at the cell
surface in the living cell. Because there is a change in the
FRET efficiency that parallels the change in association,
this provides evidence that the FRET occurs between mole-
cules within the CCPs. The observation that the energy trans-
fer increases for the AP2-BRIa but not for the AP2-BRII
when BMP2 is added qualitatively similar to the observation
that the extent of colocalization of AP2 and BRIa increases
whereas that of AP2-BRII does not. This is consistent with
the conclusion that the interactions between these molecules
occur within the coated pit at the molecular level. The first
step of clathrin-mediated endocytosis is formation of nucle-
ation sites by AP2 to recruit receptors (21,22). Eps15 protein
binds AP2 and is involved with the assembly mechanism and
early steps of endocytosis of CCPs. Targeting of Eps15 to
CCPs is due to the three EH (Eps15 homology) domains
located at the N-terminal along with a still unknown domain.
Mutant EH29 lacks both the EH-2 and EH-3 domains result-
ing in specific inhibition of CCP assembly and endocytosis.
The second step is recruitment of clathrin to form pits. The
final step is dynamin pinching of the membrane to form early
endosomes (19–21). Overexpressing the mutant dynamin
K44A inhibits the pinching off of the membrane thereforeBiophysical Journal 97(5) 1428–1435
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CCPs by potassium-free media and EH29, and endocytosis
with K44A caused a BMP-independent activation of the
BMP pathway that leads to osteoblast differentiation. The
osteoblast differentiation was measured with ALP. The trans-
fected cells with plasmids EH29 and K44A had increased
ALP activation. These data indicate that the nucleation sites
and the endocytosis of BMPRs by CCPs are necessary for
the silencing of BMP pathway and therefore affect the differ-
entiation of osteoblasts.
There has been conflicting published results of the role of
CCP with BMP signaling (4,17,18). In this study, we found
CCPs negatively regulate the Smad pathway. Supporting
this is the disruption of CCPs decreases the time it takes for
Smad1 to translocate to the nucleus (17). Disparities between
our results and other published results were a large concern of
ours and needed to be addressed. Disruption of CCPs of
SHED cells did not show a BMP independent signal, and
furthermore decreased ID1 expression (a marker for osteo-
blasts) (18). The differences of results are likely due to the
use of different cell lines and BMPs. The various BMPs do
elicit dissimilar effects of ALP, another marker for osteoblasts
(42). A second study measured Smad phosphorylation with
CCP disruption. It was unaltered, but the transcriptional effect
was decreased. We used more specific methods of disruption
compared to the other studies; it is possible this accounts for
the differences. To make sure our methods did not increase
FIGURE 5 Signaling model for the reshuttling of BMRs. Diagram model
characterizes the BMPRs, BRIa, and BRII, shuttling between membrane
domains, caveolae and CCP. CCPs are represented by AP2 (four point
star) and caveolae are differentiated by either caveolin a- and b-isoform
(overlapping circles) or caveolin b-isoform only (one circle). (A) In absence
of BMP2, BRII is localized to caveolae enriched in a- and b-isoforms (10%),
caveolae enriched in the b-isoform only (15%), and the majority in CCPs
(74%). BRIa localizes mostly to CCPs (55%). An overexpression of BRII
caused BRIa to migrate from caveolae of a- and b-isoforms into caveolae
of the b-isoform (18%). This prevents the activation of the Smad pathway.
(B) On BMP2 stimulation a redistribution of receptors occurs. BRIa and
BRII shuttle from caveolae enriched in b-isoforms into caveolae of the
a- and b-isoforms for proper Smad signaling. Building on this previous
model, BRIa does localize to CCPs (71%). No significant change was
seen with localization between BRII and CCPs.
Biophysical Journal 97(5) 1428–1435the amount of BRIa at the cell surface, we quantified the inten-
sity of BRIa. The intensities of BRIa were not significantly
different compared with the control. Therefore, the signaling
results expressed are not due to an increase amount of BRIa at
the cell surface, but due to the disruption of CCPs.
Disruption of CCPs altered the state of aggregation of
BRIa causing fewer and larger aggregates. It is possible
the aggregation of BRIa is linked to BMP-independent
signaling. The fact that there is a correlation between the
extent of aggregation and the extent of activation (comparing
control to potassium depletion) supports this linkage.
Our data indicate that BMP receptor aggregation and
distribution is regulated on the cell surface. This aggregation
is crucial for the activation of downstream signaling. Addi-
tionally, the ability to elicit a signal depends on shuttling
receptors between multiple membrane domains. Fig. 5 is a
model of BMP2 induced receptor reorganization at the cell
surface to achieve a proper Smad response. In the absence
of BMP2, surface BRII are localized to membrane domains:
caveolae ab population (10%), b-population (15%), and
CCPs (74%); ~45% of BRIa colocalizes with CCPs. BRII
recruits BRIa from Cav-1ab to Cav-1b domains. Cav-1b
binds to BRII inhibiting the phosphorylation of BRIa and
activation of the Smad pathway. Addition of BMP2 and its
binding to BRIa and BRII initiates the release of Cav-1b
and BRII. The BRII is redistributed to Cav-1ab and BRIa
is shuttled to Cav-1ab and CCPs. Although these data are
specific for BMP2 signaling, it may represent a more general
model system for receptor organization in the plasma
membrane and contribute to our understanding of how
receptor and membrane microdomain dynamics influence
a specific response.
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